- Pharmadigm has commenced a Phase II clinical trial with itsflagship compound PB005, an injectable form of the naturally-occurring steroid hormone dehydroepiandrosterone sulfate. The open-label trial will study the product in 28 severely-burned patients who require skin grafting. PB005 will be administered once a day for a period of at least six days. Clinical endpoints are rate of wound closure at skin graft donor sites and at primary burn sites.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze